Home

Tempus AI, Inc. - Class A Common Stock (TEM)

65.49
+2.89 (4.62%)
NASDAQ · Last Trade: May 17th, 3:06 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close62.60
Open64.09
Bid62.13
Ask62.40
Day's Range61.63 - 65.67
52 Week Range22.89 - 91.45
Volume10,187,506
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume12,700,043

Chart

About Tempus AI, Inc. - Class A Common Stock (TEM)

Tempus AI, Inc. is a technology company focused on leveraging artificial intelligence to revolutionize the healthcare industry. The company specializes in developing data-driven solutions that provide advanced analytics and insights for precision medicine, enhancing patient care by integrating clinical and molecular data. Tempus works with healthcare providers, researchers, and pharmaceutical companies to streamline the process of matching patients with tailored treatments, ultimately aiming to improve health outcomes and accelerate advancements in medical research. By harnessing the power of machine learning and vast datasets, Tempus is at the forefront of transforming healthcare practices and fostering innovation in the medical field. Read More

News & Press Releases

Beyond The Numbers: 11 Analysts Discuss Tempus AI Stockbenzinga.com
Via Benzinga · May 15, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development.
By Tempus AI, Inc. · Via Business Wire · May 14, 2025
Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral presentation, at the 2025 annual meeting of the Professional Society for Health Economics and Outcomes Research (ISPOR), taking place May 13-16 in Montreal, Canada. Tempus researchers are showcasing scientific and clinical studies highlighting the impact of AI and real-world data on health economics and outcomes research.
By Tempus AI, Inc. · Via Business Wire · May 13, 2025
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (and Sold)fool.com
Via The Motley Fool · May 13, 2025
Earnings Scheduled For May 6, 2025benzinga.com
Via Benzinga · May 6, 2025
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:POAI),(NYSE:TDOC),(NASDAQ:GEHC) EQNX::TICKER_END
Via FinancialNewsMedia · May 12, 2025
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robotsbenzinga.com
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.
Via Benzinga · May 12, 2025
Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies
PALM BEACH, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial Intelligence (AI) is becoming more essential in the medical markets every day, it seems. AI algorithms have demonstrated the capability to analyze vast amounts of medical data, including patient records and genetic information. This efficiency allows healthcare professionals to diagnose conditions more quickly and accurately, leading to better patient outcomes. AI-powered diagnostic tools can detect subtle patterns and indicators of diseases; this offers early detection and further works on early prevention of diseases. AI systems also help in assisting healthcare professionals with valuable tools, all these factors that offer improved diagnosis process act as a driver for the market’s growth. A report from MarketsAndMarkets projected that the global AI in medical diagnostics market is forecasted to grow at a robust CAGR of 22.5%, reaching US$1.71 billion in 2024 and an impressive US$4.72 billion by 2029. The report said: “Government initiatives towards increasing Al-based technologies, access to finance for Al-based startups, big data influx, and growing cross-industry alliances and collaborations are key drivers of this market's growth. Growth in the AI in medical diagnostics market is primarily driven by the growing demand for AI tools, increasing focus on reducing the workload of radiologists, influx of large & complex datasets, funding for AI based startups, and growing cross-industry partnerships & collaborations.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Predictive Oncology Inc. (NASDAQ: POAI), Teladoc Health, Inc. (NYSE: TDOC), GE HealthCare (NASDAQ: GEHC).
By FN Media Group LLC · Via GlobeNewswire · May 12, 2025
MarketBeat Week in Review – 05/05 - 05/09
Equities turned bullish this week on renewed hopes for progress in trade deals; next week's inflation readings could be a market mover
Via MarketBeat · May 10, 2025
Investing in CoreWeave: Key Insights on the NVIDIA‑Backed AI IPO
CoreWeave is arguably the most talked-about new stock in 2025. What is to make of this AI cloud infrastructure firm with a significant investment from NVIDIA?
Via MarketBeat · May 9, 2025
Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.
Via MarketBeat · May 8, 2025
Cathie Wood Strengthens AI Chip Holdings With Nvidia And AMD Purchases, Reduces Palantir Position By Another $38.8 Millionbenzinga.com
On Wednesday, May 7, 2025, Cathie Wood's Ark Invest Pours $24M Into Nvidia and AMD While Offloading $38.8M in Palantir Shares.
Via Benzinga · May 7, 2025
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Dealsbenzinga.com
Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ contract value.
Via Benzinga · May 7, 2025
Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here's What Data Showsbenzinga.com
Nancy Pelosi's investments over 11 years have outperformed the 'Oracle of Omaha', Warren Buffett's Berkshire Hathaway.
Via Benzinga · May 7, 2025
Cathie Wood-Backed Tempus AI Says Pharma Contracts Solid Despite Biotech Funding Challenges, Tariff Pressuresbenzinga.com
Tempus AI reassured investors that its major pharma contracts remain strong despite funding and tariff pressures.
Via Benzinga · May 7, 2025
Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Modelbenzinga.com
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology."
Via Benzinga · May 7, 2025
Tempus AI Q1 Earnings: Revenue Beat, EPS Beat, Raised FY Guidance, Shares Surgebenzinga.com
Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision medicine and patient care company reports a first-quarter adjusted loss of 24 cents per share, beating analyst estimates for a loss of 27 cents per share, according to Benzinga Pro.
Via Benzinga · May 6, 2025
Tempus Reports First Quarter 2025 Results
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025.
By Tempus AI, Inc. · Via Business Wire · May 6, 2025
Tempus AI (TEM) Stock Lower Ahead Of Q1 Earnings Report, Notetaker AI Debutbenzinga.com
Tempus AI shares are trading lower by 1.3% Tuesday afternoon. The company will report its Q1 earnings after Tuesday's market close.
Via Benzinga · May 6, 2025
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-powered clinical assistant to aid psychiatrists in generating progress notes. Notetaker, which is available in Tempus Hub, ambiently records patient sessions to generate transcripts and clinical notes that can be seamlessly stored in patients’ electronic health records.
By Tempus AI, Inc. · Via Business Wire · May 5, 2025
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.fool.com
Via The Motley Fool · May 2, 2025
Jim Cramer: Sunrun Had 'Bad Couple Of Quarters,' ExlService Holdings Is 'Solid'benzinga.com
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying BlackRock, Inc. because "it's going to be a great position."
Via Benzinga · May 2, 2025
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its support in phase I clinical trials. Since its inception in 2019, TIME has supported the rapid patient identification and site activation of clinical trials, bringing cutting-edge trials to patients in communities across the U.S. To further expand its support of phase I trials, Tempus has formed the TIME Precision Network, a group of investigators leading the phase I study platform with a focus on activating and enrolling quickly across over 40 phase I-capable research centers. Most recently, TIME enrolled the First Patient In (FPI) for multiple phase I trials.
By Tempus AI, Inc. · Via Business Wire · May 1, 2025
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback?fool.com
Via The Motley Fool · April 30, 2025
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END
Via FinancialNewsMedia · April 29, 2025